Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Cancer Research UK & EPSRC Cancer Imaging Centre Division of Radiotherapy & Imaging The Institute of Cancer Research Sutton, Surrey, UK Post-Doctoral Training Fellow – Pre-Clinical Imaging Reference number: 1239647 Pre-Clinical In Vivo MRI of Transgenic Models of Neuroblastoma The Institute of Cancer Research (ICR) is one of the world’s most influential cancer research institutes. Our mission is to make the discoveries that defeat cancer. We have a long and distinguished history of research with a major impact on the outcome for cancer patients. Our unique partnership with The Royal Marsden NHS Foundation Trust (RMH) makes us the largest comprehensive cancer centre in Europe, performing high quality original basic research and translational studies. Under the leadership of Chief Executive Professor Alan Ashworth FRS, we are committed to attracting, developing and retaining the best minds in the world. The ICR was ranked as the UK’s top academic research centre in the 2008 Higher Education Funding Council Research Assessment Exercise. Based on our publication record, citations and impact we rank among the world’s leading cancer research centres. Based within the Division of Radiotherapy and Imaging, the ICR CR-UK and EPSRC Cancer Imaging Centre is a multidisciplinary Section with research developing and evaluating methods for early detection of disease, improved diagnosis, prognosis and evaluation of response. There is particular emphasis on developing methods to assess the action of novel therapeutics and to aid therapy planning. The Pre-Clinical Imaging Team, led by Dr. Simon Robinson, is principally concerned with the further development, expansion and application of non-invasive MRI methods to identify, evaluate and qualify non-invasive imaging biomarkers of tumour pathophysiology and therapeutic response in pre-clinical tumour models in vivo. There is a strong emphasis on the development of quantitative MRI biomarkers that can be realistically translated to the clinic, to assist in planning of individual patient treatment protocols and which may find roles as biomarkers in clinical trials of anti-cancer therapies. Through a highly innovative and productive collaboration with Dr. Louis Chesler (Leader, Neuroblastoma Drug Development Team), quantitative multi-parametric MRI biomarkers are being evaluated in vivo within transgenic models of neuroblastoma, which more closely recapitulate the radiological appearance and therapeutic responses of childhood disease (Chesler & Weiss, Seminars in Cancer Biology 2012; Jamin et al, Radiology, 2012, in press). Incorporation of noninvasive imaging into pre-clinical trial designs provides a powerful, symbiotic strategy to accelerate the clinical development of new drugs for the treatment of paediatric cancer. We are now looking to recruit an early-stage post-doctoral scientist with experience in pre-clinical imaging to further enhance our imaging strategies for pre-clinical trials of novel targeted therapeutics using transgenic models of neuroblastoma. Appointment to this novel and exciting opportunity for the successful candidate will be on fixed term contract of up to 3 years in the first instance. Interested candidates should contact Dr Simon Robinson in the first instance for further information/discussion ([email protected]). Please do not send applications directly to Dr Robinson. To apply please visit http://www.icr.ac.uk/jobs/index.shtml and search using reference number 1239647 Further information is available through the jobs link at http://www.icr.ac.uk/. Closing date is 3 August 2012.